Overview

A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Carboplatin